Translational research to assist policy decisions about introducing new vaccines in developing countries

Journal of Health, Population and Nutrition

Volumn 22, Issue 3, 2004, Pages 223-231

  Clemens, John D ^a   Jodar, Luis ^a  

^a International Vaccine Institute   (South Korea)

Author keywords

Bacterial vaccines; Communicable diseases; Developing countries; Research; Vaccine development; Vaccines

Indexed keywords

BACTERIAL VACCINE; CHOLERA VACCINE; LIVE VACCINE; POLYSACCHARIDE VACCINE; SHIGELLA VACCINE; TYPHOID VACCINE;

ARTICLE; CHOLERA; CLINICAL STUDY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG SAFETY; FEASIBILITY STUDY; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INDUSTRIALIZATION; LICENSING; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NONHUMAN; POLITICS; POPULATION RESEARCH; PUBLIC HEALTH SERVICE; SHIGELLOSIS; TYPHOID FEVER; VACCINATION;

CLINICAL TRIALS; DEVELOPING COUNTRIES; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; PUBLIC POLICY; RESEARCH; VACCINATION;

BACTERIA (MICROORGANISMS);

EID: 9744262518     PISSN: 16060997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. The Jordan report: 20th anniversary: accelerated development of vaccines 2002. Bethesda, MD: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 2002. 261 p.
2. Tacket CO, Kotloff KL, Rennels MB. Initial clinical evaluation of new vaccine candidates: investigators' perspective of Phase I and II clinical trials of safety, immunogenicity, and preliminary efficacy. In: Levine M, Kaper J, Rappouli R, Liu M, Good M, editors. New generation vaccines. New York: Marcel Dekker, 2004:19-28.
3. Clemens J, Naficy A, Rao M, Koo H. Long-term evaluation of vaccine protection: methodological issues for Phase III and IV studies. In: Levine M, Kaper J, Rappouli R, Liu M, Good M, editors. New generation vaccines. New York: Marcel Dekker, 2004:29-48.
4. Vesikari T, Isolauri E, D'Hondt E, Delem A, Andre FE, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984;1:977-81.
5. Hanlon P, Hanlon L, Marsh V, Byass P, Shenton F, Hassan-King M et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987; 1: 1342-5.
6. De Mol P, Zissis G, Butzler JP, Mutwewingabo A, Andre FE. Failure of live, attenuated oral rotavirus vaccine. Lancet 1986;2:108.
7. Eskola J, Käyhty H, Takala AK, Peltola H, Rönnberg P-R, Kela E et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990;323:1381-7.
8. Ward J, Brenneman G, Letson GW, Heyward WL, and The Alaska H. influenzae Vaccine Study Group. Limited efficacy of Haemophilus influenzae type b conjugate vaccine in Alaska native infants. N Engl J Med 1990;323:1393-401.
9. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997;349: 1191-7.
10. Clemens J, Brenner R, Rao M, Tafari N, Lowe C. Evaluating new vaccines for developing countries: efficacy or effectiveness? JAMA 1996; 275:390-7.
11. Liang MH. Translational research: getting the word and the meaning right. Arthritis Rheum 2003;49:720-1.
12. Fontanarosa PB, DeAngelis CD. Translational medical research (editorial). JAMA 2003;289: 2133.
13. World Health Organization. The world health report 2003: shaping the future. Geneva: World Health Organization, 2003. 182 p.
14. Clemens JD, Sack DA, Harris JR, van Loon F, Chakraborty J, Ahmed F et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990;335:270-3.
15. Klugman KP, Gilbertson IT, Koornhof HJ, Robbins JB, Schneerson R, Schulz D et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987;2: 1165-9.
16. Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report. N Engl J Med 1987;317:1101-4.
17. Joo I. Cholera vaccines. In: Barua D, Burrows W, editors. Cholera. Philadelphia: Saunders, 1974:333-55.
18. Levine MM, Taylor DN, Ferreccio C. Typhoid vaccines come of age. Pediatr Infect Dis J 1989; 8:374-81.
19. Levinson VI, Subbotina L. [Ribosomal dysentery vaccine. II. Biological trials of active protection in guinea pigs and mice]. Zh Mikrobiol Epidemiol Immunobiol 1978;7:81-6.
20. Somerville JE, Jr., Cassiano L, Bainbridge B, Cunningham MD, Darveau RP. A novel Escherichia coli lipid A mutant that produces an anti-inflammatory lipopolysaccharide. J Clin Invest 1996;97:359-65.
21. Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 1999;67:3437-43.
22. Taylor DN, Killeen KP, Hack DC, Kenner JR, Coster TS, Beattie DT et al. Development of a live, oral, attenuated vaccine against El Tor cholera. J Infect Dis 1994;170:1518-23.
23. Hindle Z, Chatfield SN, Phillimore J, Bentley M, Johnson J, Cosgrove CA et al. Characterization of Salmonella enteritica derivatives harboring defined aroC and Salmonella pathogenicity Island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun 2002;70:3457-67.
24. Mahoney RT, Maynard JE. The introduction of new vaccines into developing countries. Vaccine 1999;17:646-52.